Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3349899
Max Phase: Preclinical
Molecular Formula: C122H193N41O38S2
Molecular Weight: 2906.27
Molecule Type: Protein
Associated Items:
ID: ALA3349899
Max Phase: Preclinical
Molecular Formula: C122H193N41O38S2
Molecular Weight: 2906.27
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC1=O
Standard InChI: InChI=1S/C122H193N41O38S2/c1-10-61(7)95-116(198)142-49-90(173)143-63(9)97(179)147-73(34-35-87(124)170)104(186)157-81(53-165)101(183)141-50-92(175)145-74(40-59(3)4)99(181)140-51-93(176)146-85(114(196)154-78(45-88(125)171)109(191)159-82(54-166)111(193)153-77(43-65-24-16-13-17-25-65)108(190)149-70(27-19-37-135-120(128)129)102(184)156-80(118(200)201)44-66-30-32-67(169)33-31-66)57-202-203-58-86(161-113(195)84(56-168)160-112(194)83(55-167)158-103(185)71(28-20-38-136-121(130)131)148-107(189)75(41-60(5)6)151-98(180)68(123)52-164)115(197)152-76(42-64-22-14-12-15-23-64)100(182)139-47-89(172)138-48-91(174)144-69(26-18-36-134-119(126)127)105(187)163-96(62(8)11-2)117(199)155-79(46-94(177)178)110(192)150-72(106(188)162-95)29-21-39-137-122(132)133/h12-17,22-25,30-33,59-63,68-86,95-96,164-169H,10-11,18-21,26-29,34-58,123H2,1-9H3,(H2,124,170)(H2,125,171)(H,138,172)(H,139,182)(H,140,181)(H,141,183)(H,142,198)(H,143,173)(H,144,174)(H,145,175)(H,146,176)(H,147,179)(H,148,189)(H,149,190)(H,150,192)(H,151,180)(H,152,197)(H,153,193)(H,154,196)(H,155,199)(H,156,184)(H,157,186)(H,158,185)(H,159,191)(H,160,194)(H,161,195)(H,162,188)(H,163,187)(H,177,178)(H,200,201)(H4,126,127,134)(H4,128,129,135)(H4,130,131,136)(H4,132,133,137)/t61-,62-,63-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,95-,96-/m0/s1
Standard InChI Key: HEZIQDLPGIHFDN-CSTIFMARSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 2906.27 | Molecular Weight (Monoisotopic): 2904.3872 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. DiMaio J, Jaramillo J, Wernic D, Grenier L, Welchner E, Adams J.. (1990) Synthesis and biological activity of atrial natriuretic factor analogues: effect of modifications to the disulfide bridge., 33 (2): [PMID:2153824] [10.1021/jm00164a031] |
Source(1):